entrance of an office building

Lonza’s Drug Product Services activities are performed in Basel, Switzerland which is situated in the three-country region of Switzerland, Germany and France, 90 km west of Zurich.  Drug Product development services are based in a 1300 m2 facility in the Stücki Business Park. The Drug Product Services unit is comprised of a number of development labs, with state-of the art analytical, formulation and drug product processing equipment.

The Drug Product Services Team is highly skilled in the development, manufacture and analysis of parenteral formulations and finished drug products for injection, infusion or implant of monoclonal antibodies, recombinant proteins, fusion proteins, antibody-drug-conjugates, oligonucleotides, vaccines, as well as virus- and cell-based therapies. The drug product analytical development & quality control (QC) group has industry-leading technical expertise in method development, product characterization and testing of biopharmaceuticals.

Specialized expertise is provided for particle characterization, container closure integrity testing, extractables/leachables, surfactant analysis, highly viscous and intravitreal (ocular injectable) drug products.

The Drug Product Services Team has extensive industry experience and can help to develop a phase-appropriate strategy for drug product or drug/device combination product clinical testing, commercialization or line extension of parenteral dosage forms.